Documentos de Stevenson J.C. | REDI

Regresar

Mostrando 6 resultados de: 6

Filtros aplicados

Área temáticas: "Enfermedades"

Subtipo de publicación

Publisher

Área temáticas

Ginecología, obstetricia, pediatría, geriatría(3)

Farmacología y terapéutica(2)

Medicina y salud(2)

Fisiología humana(1)

Salud y seguridad personal(1)

Área de conocimiento

Ginecología(1)

Medicina interna(1)

Año de Publicación

Origen

Palabras Claves

Bisphosphonates(2)

Aromatase inhibitors(1)

BRCA gene mutation(1)

Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.

Palabras claves:

Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.

Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide

Abstract: Introduction Postmenopausal osteoporosis is a highly prevalent disease. Prevention through lifestyle

Palabras claves:

calcium, diet, Excess-calcium risk, Postmenopausal osteoporosis, prevention

Cano A., Goulis D.G., Lambrinoudaki I., Lopes P., Mishra G.D., Mueck A., Peter A. Chedraui, Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Tuomikoski P.

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Abstract: Background Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal ost

Palabras claves:

Alendronate, Bisphosphonates, Denosumab, Drug holiday, Risedronate, Zoledronic acid

Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.

Osteoporosis management in patients with breast cancer: EMAS position statement

Abstract: Aromatase inhibitors (AIs) are the first-line recommended standard of care for postmenopausal estrog

Palabras claves:

adjuvant therapy, Aromatase inhibitors, Bisphosphonates, Breast Cancer, Denosumab, fractures, OSTEOPOROSIS, screening

Ceausu I., Depypere H., Faustino R. Pérez-López, Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A., van der Schouw Y.T.

Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement

Abstract: Background Ovarian cancer is a leading cause of female gynecological cancer-related death, and there

Palabras claves:

bilateral oophorectomy, Bilateral salpingectomy, BRCA gene mutation, Combined oral contraceptives, Fallopian tubes cancer, hysterectomy, Non-steroid anti-inflammatory drugs, obesity, Ovarian borderline tumors, Ovarian Cancer, smoking

Ceausu I., Depypere H., Faustino R. Pérez-López, Kehoe S., Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P.

Menopause and diabetes: EMAS clinical guide

Abstract: Introduction: Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently

Palabras claves:

menopausal hormone therapy, MENOPAUSE, Type 2 Diabetes mellitus

Anagnostis P., Cano A., Goulis D.G., Jaremek J.D., Lambrinoudaki I., Lopes P., Meczekalski B., Mishra G.D., Mueck A., Paschou S.A., Peter A. Chedraui, Rees M., Rogowicz-Frontczak A., Senturk L.M., Simoncini T., Slopien R., Stevenson J.C., Stute P., Tuomikoski P., Wender-Ozegowska E., Zozulinska-Ziolkiewicz D.